Compare Enbridge Inc (ENB) vs Illumina, Inc. (ILMN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Enbridge Inc vs Illumina, Inc. — how do they compare? Enbridge Inc trades at $51.77 (market cap $112.62B), while Illumina, Inc. trades at $190.62 (market cap $29.12B). The key difference: Enbridge Inc is far larger — about 3.9× Illumina, Inc.'s market cap, and Enbridge Inc pays a 5.34% dividend while Illumina, Inc. pays none. Which is the better fit depends on your goals.
| ENB | ILMN | |
|---|---|---|
Market Cap | $112.62B | $29.12B |
Sector | Energy | Health |
52-Week High | $58.04 | $205.10 |
52-Week Low | $45.23 | $91.00 |
Enterprise Value | $196.53B | $30.48B |
Dividend Yield | 5.34% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Enbridge (ENB) trades at $51.39, up 0.21% with a bearish technical signal despite recent earnings beats. The company maintains strong fundamentals with $65.2B revenue, 11.5% net margin, and consistent dividend growth spanning 31 years. Recent Q2 2026 results exceeded expectations with $0.46 EPS versus $0.43 estimate, supported by robust pipeline and utility performance. Analyst sentiment is balanced with 48% buy ratings while technical indicators show oversold conditions with RSI at 14.8.
ENB presents a compelling income opportunity with 5.3% dividend yield and $41B growth pipeline, though faces regulatory risks from Line 5 litigation and Wisconsin tribal land dispute. The stock's current valuation at 27.8x P/E appears reasonable given stable cash flows, but investors should monitor debt levels approaching 49% of assets and potential project delays affecting growth execution.
Illumina (ILMN) trades at $191.79, up 2.04% today, with a neutral technical signal and strong fundamental recovery. The stock shows bullish moving averages but faces resistance near $194. Recent earnings beats and a return to profitability in 2025, with $850M net income, highlight operational turnaround. Revenue remains stable around $4.3B, supported by robust gross margins of 66.38%.
Outlook is positive with analyst consensus Buy rating and $201.58 price target, though high P/E of 35.98 poses valuation risk. Key opportunities include sequencing demand and AI partnerships, while risks involve debt levels and competitive pressures. Institutional activity is mixed, with some funds increasing stakes amid earnings momentum.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Enbridge Inc
Enbridge owns extensive midstream assets that transport hydrocarbons across the U.S. and Canada. Its pipeline network consists of the Canadian Mainline system, regional oil sands pipelines, and natural gas pipelines. The company also owns and operates a regulated natural gas utility and Canada's largest natural gas distribution company. Finally, the firm has a small renewables portfolio primarily focused on onshore and offshore wind projects.
Read more on ENB →About Illumina, Inc.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (less than 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Read more on ILMN →
